Dual GIP/GLP-1 research
99%+ · 0.5mg · Tablets · MW: 4813.45
Bulk discount
3+ pcs
€104.50
−5%
5+ pcs
€99.00
−10%
10+ pcs
€93.50
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ guaranteed — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
1-3 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Card via Stripe or Cash on Delivery
Tirzepatide Tablets 500 mcg × 25
Dual GIP / GLP-1 Receptor Agonist | Oral Tablet Format | Next-Gen Incretin Research
In short
Strongly suppresses appetite and prolongs fullness, helping you achieve significant weight loss without feeling hungry.
Best sellers
Related resources
Scientific review
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed on
Tirzepatide combines GIP and GLP-1 receptor agonism in a single 39-amino-acid molecule with a 20-carbon fatty acid moiety for albumin binding (~5-day half-life). The dual mechanism activates both incretin axes simultaneously — a strategy validated by SURPASS (T2D) and SURMOUNT (obesity) Phase 3 programs. SURMOUNT-1 (NEJM 2022) reported 22.5% mean weight loss at 15 mg/week, the largest effect size yet documented for pharmacological weight reduction.
SURMOUNT-1: 22.5% body-weight reduction at 15 mg/week (NEJM 2022) SURPASS-2: HbA1c -2.46% vs semaglutide -1.86% (NEJM 2021) ~5-day plasma half-life — weekly injectable reference Dual GIP/GLP-1 — only twincretin currently FDA-approved
Tirzepatide is a balanced co-agonist at GIP-R and GLP-1R. GIP activation enhances first-phase insulin response and lipid handling; GLP-1 activation provides appetite suppression, gastric-emptying delay, and glucagon suppression. The synergy yields superior weight and glycemic outcomes versus selective GLP-1 agonists, though the mechanism of the additive effect remains under investigation.
SURMOUNT-1 (NEJM 2022, n=2539) showed 22.5% body-weight reduction at 15 mg/week over 72 weeks — the largest pharmacological weight reduction documented to date.
Adverse-event profile resembles mono-agonists with similar gastrointestinal predominance. Nausea, vomiting, diarrhea, and constipation are most common during titration. Acute pancreatitis is a class-effect signal. The dual mechanism does not appear to add novel safety signals beyond the class to date, though long-term cardiovascular data is still accumulating (SURPASS-CVOT ongoing).
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Human | 2539 participants | 72 weeks | NEJM 2022
Jastreboff et al. reported 22.5% mean body-weight reduction at 15 mg weekly tirzepatide over 72 weeks — the largest effect size documented for pharmacological weight management.
View the studyTirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)
Human | 1879 participants | 40 weeks | NEJM 2021
Frías et al. directly compared tirzepatide and semaglutide; tirzepatide produced superior HbA1c (-2.46% vs -1.86%) and weight outcomes.
View the study
Out of stockfor visceral fat
for weight loss
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
